Travelzoo Inc. (NASDAQ:TZOO) reported that financial results for Q3 ended 2014 fell short of analysts' expectations, despite returning to profit from a loss in the year-ago period. Travelzoo Inc. (NASDAQ:TZOO) posted Q3 GAAP earnings of $2.5 million or $0.17 per share, compared with the prior-year period's loss of $19.04 million or $1.24 loss per share. Adjusted earnings was $286,000 or $0.02 per share, versus $2.96 million or $0.19 per share in the same quarter the previous year. Revenue was $33.5 million, down 10% from $37.26 million in the same quarter last year. Analysts polled by Capital IQ were expecting EPS of $0.13 on revenues of $35.18 million.Syntel, Inc. (NASDAQ:SYNT) a provider of information-technology and knowledge-process services, Thursday reported Q3 earnings above analysts' consensus despite lower-than-expected revenue, and raised its 2014 earnings view even as the company cut its revenue guidance. The company posted Q3 net income of $61.6 million, or $1.47 per share, up from $59.4 million, or $1.42 per share, a year earlier. Analysts polled by Capital IQ were looking for $1.40 per share. Net revenue rose to $228.3 million from $209.9 million a year earlier, missing analysts' mean estimate of $237 million.Gross margin slipped to 41.4% from 46.6% in the prior-year period as selling, general and administrative expenses rose to 11.6% of revenue from 10.7% a year earlier. "During the third quarter, we experienced some temporary headwinds in our Health Care and Life Science segment that have impacted our full-year 2014 growth outlook," said Syntel CEO and President Nitin Rakesh. Syntel, Inc. (NASDAQ:SYNT) said it now expects 2014 revenue in a range of $908 million to $915 million, down from its prior forecast of $920 million to $940 million. However, Syntel raised its EPS forecast for 2014 to a range of $5.60 to $5.70, from its previous view of $5.50 to $5.65. Analysts recently were projecting $932 million and $5.62, respectively. SYNT trades in a 52-week range of $76.52 to $97.23.Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a pharmaceutical company that discovers, develops and intends to commercialize differentiated medicines, said Thursday that it has commenced a Phase II clinical trial evaluating linaclotide for the treatment of adults suffering from opioid-induced constipation (OIC). Linaclotide is a guanylate cyclase-C (GC-C) agonist approved by the FDA for the treatment of adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Linaclotide is not currently approved for the treatment of OIC.The randomized, double-blind, placebo-controlled, multi-site Phase II clinical trial is expected to enroll 240 adult patients with chronic, non-cancer pain who have been receiving a stable dose of an opioid analgesic and suffer from constipation, defined as fewer than three spontaneous bowel movements (SBMs) per week. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) notes that patients will be randomized to receive 145 mcg of linaclotide, 290 mcg of linaclotide, or placebo for eight weeks. The primary endpoint of the trial is an increase in SBM frequency. Data are expected in the second half of 2015. The clinical trial is being conducted jointly by IRWDand Actavis plc (ACT), the company's co-development and co-promotion partner for linaclotide in the U.S.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
